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Background: The details of the clinical characteristics of patients with chronic pulmonary
aspergillosis (CPA) have not been fully understood.
Method: One hundred twenty-nine consecutive patients with isolation of Aspergillus species
by culture from respiratory specimens who attended our hospital between October 2001 and
September 2009 were enrolled. Patients diagnosed with chronic pulmonary aspergillosis
(CPA) were retrospectively reviewed for clinical characteristics and prognosis, compared with
patients with Aspergillus species colonization.
Results: Forty-two (32.6%) were diagnosed with CPA, whereas 87 (67.4%) with colonization.
Aspergillus fumigatus was significantly more frequently detected in the CPA group than in
the colonization group. Regarding underlying diseases, CPA patients had a significantly higher
prevalence of a history of pulmonary tuberculosis and diabetes mellitus than colonization
patients. There were no significant differences between the CPA and colonization group in
Aspergillus antigen titers. Positivity for Aspergillus precipitating antibody was 74.3% in CPA
and 15.8% in colonization, respectively. Sensitivity and specificity of Aspergillus precipitating
antibody for the determination of CPA was 74.4% and 84.1%, respectively.Patients with CPA had
significantly shorter survival than patients with colonization (mortality rate 50.0% vs. 13.8%,
observation periods: 28.7  26.6 months) (p < 0.0001). Multivariable analysis revealed that
BMI was an independent predictor of prognosis (Odds Ratio, 1.973; p Z 0.0223).
Conclusions: CPA is a disease with a poor prognosis, which shows distinct clinical characteris-
tics from colonization.
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Characteristics of chronic pulmonary aspergillosis 725Introduction pleural thickening with/without fungal ball. 3) Isolation ofAspergillus species are ubiquitous, saprophytic fungi
commonly found in humid soil, water, and decaying organic
material of various climatic conditions. Aspergillus species
can reach the respiratory tract by airborne transmission,
causing various pulmonary diseases. Although the patho-
genesis of Aspergillus infection has been incompletely
understood, it is thought that the quantity and virulence of
inhaled organisms and the adequacy of host defense are
important factors for disease development. In intact host
defense, namely healthy persons, the spores are eliminated
by mucociliary clearance and by pulmonary macrophages
and neutrophils, resulting in limitation of the proliferation
and spread of Aspergillus organisms; however, impaired host
defense by underlying pulmonary disease or decreased
immune function can cause several forms of clinical condi-
tions, including disease (i.e. pulmonary aspergillosis) and
colonization.1 Pulmonary aspergillosis is categorized into
invasive aspergillosis, chronic forms of aspergillosis, and
allergic forms of aspergillosis (i.e. allergic bronchopulmo-
nary aspergillosis (ABPA)).2 The definition of chronic pulmo-
nary aspergillosis (CPA) has been not clearly defined and has
been described with a variety of names because of a wide
range of clinical, radiologic, and anatomicopathologic enti-
ties. Recently, it has been accepted that CPAmainly consists
of chronic necrotizing pulmonary aspergillosis (CNPA) and
chronic cavitary pulmonary aspergillosis (CCPA).3 CNPA
causes progressive destruction of the lung, while CCPA cau-
ses multiple cavities, with or without aspergilloma, accom-
panied by pulmonary and systemic symptoms. Although
there have beenmany reports on invasive and allergic types,
there are few reports of the chronic type. In this study, based
on the isolation of Aspergillus species, we evaluated the
clinical characteristics and prognosis of patients with CPA.
Materials and methods
Patients
We retrospectively collected consecutive patients with isola-
tion of Aspergillus species by culture from respiratory speci-
mens (sputum or samples obtained by bronchoscopy) who
attended Tenryu Hospital, National Hospital Organization
between October 2001 and September 2009. Respiratory
specimens were cultured on potato-dextrose agar, and
selected colonies were identified as Aspergillus by standard
morphological procedures. The present study was conducted
according tohospital ethics committeeapproval and informed
consent was obtained according to the hospital’s guidelines.
Diagnosis
Chronic pulmonary aspergillosis (CPA), such as chronic
necrotizing pulmonary aspergillosis (CNPA) and chronic cavi-
tary pulmonary aspergillosis (CCPA),was diagnosed according
to the following criteria (4): 1) Clinical symptoms: fever,
cough, sputum production, and weight loss of 1e6 months’
duration. 2) Radiologic findings showing cavitary pulmonary
lesion with evidence of paracavitary infiltrates and adjacentAspergillus species by culture from sputum or samples ob-
tained by bronchoscopy. 4) Exclusion of similar presentations
caused by active tuberculosis, other mycoses, neoplasm,
abscess, Wegener’s granulomatosis etc. and 5) Exclusion of
invasive pulmonary aspergillosis, allergic forms of aspergil-
losis, and simple aspergilloma. Colonization was defined as
isolation of Aspergillus species with clinical or radiographic
evidence that was consistent with the possibility that Asper-
gillus species were part of their flora, moreover, had neither
radiological nor clinical CPA findings.5
Aspergillus serological examination
Aspergillus galactomannan antigen tests were performed
using the platelia Aspergillus enzyme-linked immunoassay
(EIA) (Bio-Rad, Marnes-la-Coquette, France). Aspergillus
precipitating antibody tests were performed by the Ouch-
terlony method (Merica Diagnostics, Camberley, Surrey,
UK). The (1/3) b-D glucan assay was carried out by the MK
method (Seikagaku Corporation, Tokyo, Japan). Healthy
volunteers free from respiratory disease were included as
normal controls.
Statistical analysis
The values are expressed as the mean  SD. For nonpara-
metric statistical evaluation of differences between the
two groups, Fisher’s exact probability test or the Man-
neWhitney U test was used. Survival was analyzed using
KaplaneMeier analysis and the log rank test. Prognostic
factors were determined by univariate and multivariate
analysis. Data was analysed using Statview v5.0 (SAS) soft-
ware.p values < 0.05 were considered significant.
Results
Patients characteristics
Thepatient’s characteristics are summarized inTable 1.Of 129
enrolled patients (82 males and 47 females; 73.2 12.0 years
old),42 (32.6%)(31malesand11 females;75.111.3yearsold)
were diagnosed with chronic pulmonary aspergillosis (CPA),
whereas 87 (67.4%) (51 males and 36 females; 72.3  12.2
years) were diagnosed with colonization. CPA patients had
a significantly lower body mass index (BMI) than colonization
patients (17.1  2.8 vs. 20.2  2.9 kg/m2; p < 0.0001).
Consistent with previous reports,3,6,7 most underlying diseases
were sequelaeofmycobacteriumsuchas tuberculosis andnon-
tuberculosis mycobacterium in both groups. CPA patients had
a significantly higher prevalence of pulmonary tuberculosis
(50.0 vs. 17.2%; p Z 0.0003) and diabetes mellitus (23.8 vs.
5.7%; pZ 0.0061) than colonization patients.
Isolation of Aspergillus species
As shown in Table 2, 187 Aspergillus species were isolated
from 129 patients. Of 187 Aspergillus species, 90 were
Aspergillus fumigatus (48.1%), 56 were Aspergillus niger
(30.0%), 12 were Aspergillus flavus (6.4%), and 29 were
Table 1 Patients characteristics.
CPA Colonization p value
(n Z 42) (n Z 87)
Age(yrs) 75.1  11.3 72.3  12.2 N.S.
Gender(M/F) 31/11 51/36 N.S.
BMI（kg/m2) 17.1  2.8 20.0  2.9 <0.0001
Underlying disease
TB 21(50.0%) 15(17.2%) 0.0003
NTM 15(35.7%) 30(34.5%) N.S.
COPD 6(14.3%) 13(14.9%) N.S.
Interstitial pneumonia 2(4.8%) 7 (8.0%) N.S.
Pneumoconiosis 2(4.8%) 1 (1.1%) N.S.
Bronchiectasis 3(7.1%) 9(10.3%) N.S.
Autoimmune disease 3(7.1%) 8 (9.2%) N.S.
Diabetes 10(23.8%) 5 (5.7%) 0.0061
Malignancy 13(30.9%) 14(16.1%) N.S.
Chronic hepatitis 6(14.3%) 4 (4.6%) N.S.
Steroid therapy 1 (2.4%) 2 (2.3%) N.S.
CPA; chronic pulmonary aspergillosis, BMI; body mass index, TB;
tuberculosis, NTM; non-tuberculous mycobacterium, COPD;
chronic obstructive pulmonary disease, N.S.; not significant.
726 H. Ohba et al.unidentified Aspergillus (i.e. Aspergillus sp) (15.5%). A.
fumigatus was significantly more frequently detected in the
CPA group than in the colonization group (68.0 vs. 34.8%;
p < 0.0001), whereas A. niger was significantly less
detected in the CPA group than the colonization group (14.7
vs. 40.2%; p Z 0.0002).
Laboratory findings
Serum C-reactive protein (CRP) (4.01  5.18 vs.
2.26  4.47 mg/ml; p Z 0.0011) and (1/3) b-D glucan
(26.7  44.2 vs. 6.86  10.7 pg/ml; pZ 0.0023) in the CPA
group were statistically higher than in the colonization
group. Serum albumin in the CPA group was significantly
lower than in the colonization group (3.32  0.54 vs.
3.81  0.48 g/dl; p < 0.0001). There were no significant
differences in white blood cell count (7183  2938 vs.
6462  3136/mm3) and serum total protein (7.14  0.84 vs.
6.68  0.66 g/dl) between the two groups.
Aspergillus serological antigen and antibody test
As shown in Fig. 1A, Aspergillus antigen titers in the CPA
group were significantly higher than in the control group
(0.92  1.09 vs. 0.39  0.28; pZ 0.0056), but there was noTable 2 Isolation of Aspergillus species.
Total C
(n Z 187) (n
Aspergillus fumigatus 90 (48.1%) 5
Aspergillus niger 56 (30.0%) 1
Aspergillus flavus 12 (6.4%)
Aspergillus sp. 29 (15.5%) 1
CPA; chronic pulmonary aspergillosis, N.S.; not significant.significant difference between the CPA and colonization
groups (0.92  1.09 vs. 0.61  0.58).Since the area under
curve (AUC) of the receiver-operating characteristic (ROC)
for discriminating between CPA and colonization groups
was 0.574 (Fig. 1B), we could not find an optimal cut-off
point of Aspergillus antigen titers. Positivity for Asper-
gillus precipitating antibody was 74.3% (29/tested 39) in
the CPA, 15.8% (10/tested 63) in the colonization, and
0%(0/39) in the control group, respectively (Fig. 1C).
Sensitivity and specificity of Aspergillus precipitating anti-
body for the determination of CPA were 74.4% and 84.1%,
respectively.Prognosis
The observation period was 28.7  26.6 months. There
were 21 (50.0%) deaths in 42 CPA patients and 12 (13.8%)
deaths in 87 colonization patients. In CPA patients, 18
(85.7%) were CPA-related deaths, while 3 (14.3%) were lung
cancer-related deaths. In KaplaneMeier survival analysis
from the time of diagnosis of CPA and colonization, patients
with CPA had significantly shorter survival than patients
with colonization (p < 0.0001, log rank test)(Fig. 2).Prognostic factor in patients with CPA
By univariate analysis, BMI (Odds Ratio, 1.858; pZ 0.0142)
and serum albumin (Odds Ratio, 6.515; p Z 0.0165) were
predictors of prognosis in CPA patients (Table 3A).
Furthermore, multivariate analysis revealed that BMI was
an independent predictor of prognosis (Odds Ratio, 1.973;
p Z 0.0223) (Table 3B). In the CPA patients, 32 (76.1%)
underwent anti-fungal therapy, including 22 (69%) itraco-
nazole, 12 (38%) micafungin, 8 (25%) voriconazole and 3
(9.4%) intracavitary instillation of Amphotericin B at the
discretion of the participating physicians. Neither univar-
iate nor multivariate analysis indicated that anti-fungal
therapy significantly affected survival.Discussion
The present long-term follow-up study, based on Asper-
gillus species isolation from respiratory samples, demon-
strated that CPA is a high mortality disease. In addition,
patients with CPA were distinct from colonization regarding
the type of species, underlying disease, precipitating
antibody sensitivity, and prognosis.PA Colonization p value
Z 75) (n Z 112)
1 (68.0%) 39 (34.8%) <0.0001
1 (14.7%) 45 (40.2%) 0.0002
3 (4.0%) 9 (8.0%) N.S.
0 (13.3%) 19 (17.0%) N.S.
Figure 1 Aspergillus serological test. (A) Aspergillus antigen
titer levels in CPA, colonization, and control group. Aspergillus
antigen titer levels are significantly higher in the CPA group than
in the control group (pZ 0.0056), while there are no significant
difference between the CPA and the colonization group, the
colonization and the control group, respectively. (B) Receiver-
operating characteristic (ROC) curve analysis of Aspergillus
antigen titer levels to discriminate between CPA and colonization
patients. Area under curve (AUC) of ROC is 0.574. (C) Aspergillus
precipitating antibody test in CPA, colonization, and control
group.Antibody-positive is 74.3% (29/39) in theCPA, 15.8%(10/63)
in thecolonization,and0%(0/39) in thecontrol group, respectively.
Figure 2 KaplaneMeier curves of survival probability from
the time of diagnosis of CPA (n Z 42) and colonization
(n Z 87). CPA patients show significantly shorter survival than
colonization patients (p < 0.0001, log rank test).
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documented. The first review report by Binder and
coworkers8 showed that the mortality rate was 19% with
a median follow-up time of 15 months. Camuset and
coworkers6 reported that the mortality rate was 8% with
a median follow-up time of 10 months. In contrast, our
study showed a high mortality rate (50%) with a follow-up
time of 28.7  26.6 months. Consistent with our study,
a report by Nam and coworkers,9 including 43 CNPA patients
with a median follow-up of 15 months, showed that the
mortality rate was 51%. The reported prognosis of CPA
patients may vary due to various follow-up periods, severity
of underlying disease, delayed diagnosis, and/or the initi-
ation of effective therapy.
Since CPA is a progressive lung destruction disease,
systemic treatment with anti-fungal agents could be taken
into consideration.10,11 The Infectious Diseases Society of
America (IDSA) recommended the use of orally adminis-
tered itraconazole or voriconazol for CPA.2Dupont reported
that in 14 patients treated with itraconazole, 57% (8/14)
were cured and 35% (5/14) were stabilized with a follow-up
time of 11 months.12 Similarly, De Beule and coworkers
reported that in 44 patients treated with itraconazole, 66%
(29/44) showed marked improvement or cure.13 Regarding
voriconazole treatment, Camuset and coworkers6 observedTable 3A Mortality predictive factors in patients with CPA
using univariable analysis.
Odds ratio 95%CI p value
Sex(male) 0.455 0.101e2.049 0.3052
Age 0.991 0.936e1.048 0.7405
Body mass index 1.858 1.132e3.047 0.0142
TB 1.833 0.374e8.986 0.4548
NTM 0.952 0.200e4.539 0.9512
C-reactive protein 0.876 0.757e1.014 0.0766
Albumin 6.515 1.408e39.147 0.0165
bD glucan 0.990 0.975e1.006 0.2210
Aspergillus antigen 1.284 0.679e2.425 0.4420
Therapy (Yes) 0.237 0.044e1.280 0.9430
CPA; chronic pulmonary aspergillosis, TB; tuberculosis, NTM;
non-tuberculous mycobacterium.
Table 3B Indipendent mortality predictive factors in
patients with CPA using logistic regression analysis.
Odds ratio 95%CI p value
Age 0.959 0.868e1.058 0.4022
Body mass index 1.973 1.101e3.533 0.0223
C-reactive protein 0.897 0.757e1.064 0.2114
Therapy(Yes) 0.247 0.019e3.181 0.2835
CPA; chronic pulmonary aspergillosis.
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after a median follow-up time of 10 months. Sambatakou
and coworkers14 in a prospective study found an 80%
response rate; however, they were a small number of
nonrandomized or open-label studies. Recently, Kohno and
coworkers in a prospective, randomized, open-label study
reported that intravenous micafungin was as effective as
intravenous voriconazole and significantly safer than as an
initial treatment of CPA.15 Notably, our study showed that
anti-fungal therapy did not affect the survival of CPA
patients statistically, indicating that larger, randomized
control studies are necessary to establish standard thera-
peutic strategy.
Malnutrition is a well-known complication of chronic or
advanced pulmonary diseases such as COPD, tuberculosis,
and cancer. BMI is a simple biochemical parameter related
to nutritional status. Several studies have shown that a low
BMI is associated with increased mortality in those
patients.16,17 In our study, low BMI was demonstrated to
have an independent effect on mortality in CPA patients.
Although the mechanisms of this are not clear, the
management of nutrition may play an important role in
following up CPA patients.
There are approximately 200 species of Aspergillus;
however, only a few are known to be pathogenic in humans,
including A. fumigatus, A. niger and A. flavus.4 According
to a recent large-scale epidemiological report,5 patients
with CPA as well as colonization were most often affected
by A. fumigatus, followed by A. niger, A. flavus. In our
study, CPA patients were basically consistent with the
previous report, whereas in our colonization patients, A.
niger (40.2%) was detected more than A. fumigatus
(34.8%). The reason for this might depend on the number of
colonization samples (our study: 112; previous study: 735).
Aspergillus antibody and/or antigen have been often
measured for the serodiagnosis of pulmonary aspergillo-
sis.For invasive pulmonary aspergillosis (IPA), the cut-off
index of Aspergillus galactmannan antigen (1.5 or  0.5)
has been determined by several studies and is useful for
diagnosis18,19; however, since it was reported that the
sensitivity to the cut-off valuewas low in CPA (13.3e50%),6,20
the usefulness of Aspergillus galactmannan antigen for CPA
remains to be clarified. In our study, therewere no significant
differences between CPA and colonization. Furthermore, by
ROC analysis we could not find an appropriate cut-off point to
discriminate between CPA and colonization. In contrast, it
was accepted that the Aspergillus participating test was
suitable for the diagnosis of chronic forms of aspergillosis.1,2
Similar to a previous report,20 our study showed high sensi-
tivity and specificity for CPA, and no reaction to the normalcontrol. Thus, theAspergillusparticipating test appears to be
a more helpful tool than galactmannan antigen test for the
diagnosis of CPA.
The present study had several limitations. First, it was
retrospective; in particular, systemic anti-fungal therapy
was performed at the discretion of the participating
physicians. Second, since it was based on the isolation of
Aspergillus species, probable CPA patients who had typical
radiographic findings and a positive Aspergillus partici-
pating test without isolation of Aspergillus species might
have been excluded; however, we believe that the present
study revealed the principles of the CPA condition.
In conclusion, the clinical characteristics and prognosis
of patients with CPA were different from colonization.
Since our study demonstrated that CPA has a poor prog-
nosis, the long-term effects of systemic therapy, as well as
the involvement of Aspergillus species in the development
of a poor condition, need to be further investigated.
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